Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases. It operates a target discovery platform that supports a pipeline of first-in-class assets.
4 investors
Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology. The company serves biopharma, agritech, and industrial biotech companies seeking to engineer organisms at scale.
4 investors
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
4 investors
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma. The company works at the intersection of cancer genomics and immunotherapy and is based at MBC Biolabs in San Carlos, California.
4 investors
Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions. The platform aims to produce therapeutics for patients with cancer, neurodegenerative diseases, and rare disorders.
4 investors
GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources, implanted during brain tumor removal surgery to deliver targeted radiation at the surgical site. It is indicated for patients with operable brain tumors, including newly diagnosed and recurrent glioblastoma, brain metastases, and recurrent meningiomas.
4 investors
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
4 investors
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.
4 investors
Hedera Dx provides hospital in-house laboratories with a full suite of NGS genomic tumor profiling solutions, including FFPE, ctDNA and RNA-only testing, plus software that generates clinical reports linking tumor sequences to approved therapies. It also supports real-world evidence generation for health systems, patients and drug development programs, with a stated focus on European hospital laboratories.
4 investors
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications. The company focuses on targeted cytotoxic therapy for cancer, drawing on human therapeutics derived from metagenomes.
4 investors
Holoclara develops therapeutics derived from symbiotic intestinal organisms (helminths) that modulate inflammation, metabolism, and tissue regeneration to address chronic disease, immune-related conditions, and aging. The company aims to reintroduce beneficial worm-derived components without live worms.
4 investors
Vitra develops reproductive therapies that mature eggs outside the body in a controlled environment, aiming to reduce or eliminate the hormone injections required in conventional IVF. The women-led biotech company builds technology intended to fit existing IVF clinical workflows to make fertility care safer and more accessible for patients and clinicians.
4 investors
HotHouse Therapeutics uses AI combined with plant bioengineering to discover and produce complex natural-product-based molecules, including vaccine adjuvants and small-molecule therapeutics, for pharma, biotech, and global health. Through its BotanAI and BotanBio platforms, it engineers plants as biofactories to synthesize new-to-nature compounds.
4 investors
Hydregen develops biocatalysis platform technologies that integrate into existing chemical manufacturing infrastructure, aiming to cut process costs by 40-50% while lowering energy use and carbon emissions. It sells to chemical manufacturers, supporting UK and EU needs for secure critical chemical supply chains.
4 investors
Ignota Labs uses SAFEPATH, a proprietary AI platform combining machine learning with bioinformatics and cheminformatics data, to identify and resolve drug safety and toxicity problems. It focuses on drugs that failed in preclinical, Phase 1, or Phase 2 clinical trials due to safety issues, aiming to turn them around and bring them to patients faster.
4 investors
The page is a stock price information page (share price, trading volume, and market cap history) rather than a descriptive company page, so it provides no usable detail about what the company does.
4 investors
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy. It focuses on therapies for patients with limited treatment options in cardiometabolic and cardiovascular conditions.
4 investors
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.
4 investors
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
4 investors
Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases. Its approach targets multiple biological pathways at once rather than a single protein or mechanism.
4 investors
ImmunoForge is a South Korean drug development company that builds a pipeline of therapeutics based on its ELP (elastin-like polypeptide) half-life extension platform and a blood-brain-barrier shuttle platform (LMT15). Its programs include candidates for chronic myelogenous leukemia (KF1601) and Duchenne muscular dystrophy cardiomyopathy (Pemziviptadil).
4 investors
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases. The company focuses on advancing treatments in cancer immunotherapy and inflammation-related conditions.
4 investors
ImpriMedicine provides live-cell-based predictive analytics to identify effective drugs for treating blood cancers in dogs and cats, offering patient-specific drug response predictions. The company serves veterinary oncology and drug development efforts in the animal health field.
4 investors
Inari applies artificial intelligence and gene editing to accelerate plant breeding, delivering crop improvement solutions for farmers focused on soybeans, corn, and wheat across broadacre agriculture.
4 investors